MDXG on Nasdaq

MIMEDX GROUP, INC.

Surgical and medical instruments and apparatus company, listed on Nasdaq (MDXG).

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with ACCURAY INC, CryoLife or GLAUKOS Corp, or pick any stock.

  • TickerMDXG on Nasdaq
  • IndustrySurgical & Medical Instruments & Apparatus
  • Business address1775 W Oak Commons Court, Ne, Marietta, Ga 300622
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

82.6%Gross margin3
15.3%Operating margin3
11.6%Net margin3
20.0%Revenue growth, 20253
18.9%Return on equity3
0.06×Debt to equity3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Wound brought in 66% of the revenue MIMEDX GROUP, INC. broke down this way in fiscal 2025.

  1. Wound$276.3M366%up 20% from 2024
  2. Surgical$142.3M334%up 21% from 2024
Products and services by year
Products and services202320242025
Wound$205.7M$231.0M$276.3M
Surgical$115.8M$117.9M$142.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue17¢$73.0M
  • Research and development4¢$15.1M
  • Selling, general and admin63¢$266.2M
  • Income tax4¢$17.7M
  • Profit12¢$48.6M

Out of $418.6M in revenue.3

Where each dollar of operating cash went, fiscal 2025

  • Kept or used elsewhere100¢$74.0M

Out of $74.0M of cash from operations.3

Financial statements

Revenue45673$418.6M in 2025+40% since 2019
0$200.0M$400.0M$600.0M2019: $299.3M$299.3M20192020: $248.2M$248.2M2020−17%2021: $242.0M$242.0M2021−3%2022: $267.8M$267.8M2022+11%2023: $321.5M$321.5M2023+20%2024: $348.9M$348.9M2024+9%2025: $418.6M$418.6M2025+20%
Gross profit45673$345.6M in 2025+35% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $256.2M$256.2M20192020: $208.9M$208.9M2020−18%2021: $202.4M$202.4M2021−3%2022: $219.5M$219.5M2022+8%2023: $266.8M$266.8M2023+22%2024: $288.8M$288.8M2024+8%2025: $345.6M$345.6M2025+20%
Operating income45673$63.9M in 2025
-$50.0M0$50.0M$100.0M2019: -$21.2M-$21.2M20192020: -$45.4M-$45.4M2020+115%2021: -$7.1M-$7.1M2021−84%2022: -$14.7M-$14.7M2022+109%2023: $37.1M$37.1M20232024: $58.9M$58.9M2024+59%2025: $63.9M$63.9M2025+9%
Net income45673$48.6M in 2025
-$50.0M0$50.0M$100.0M2019: -$25.6M-$25.6M20192020: -$49.3M-$49.3M2020+93%2021: -$10.3M-$10.3M2021−79%2022: -$30.2M-$30.2M2022+194%2023: $58.2M$58.2M20232024: $42.4M$42.4M2024−27%2025: $48.6M$48.6M2025+15%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Net sales$418.6M$348.9M$321.5M
Cost of sales$73.0M$60.1M$54.6M
Gross profit$345.6M$288.8M$266.8M
Selling, general and administrative$266.2M$225.1M$211.1M
Research and development$15.1M$12.3M$12.7M
Investigation, restatement and related$0-$8.7M$5.2M
Amortization of intangible assets$439.0K$765.0K$762.0K
Impairment of intangible assets$0$446.0K$0
Operating income$63.9M$58.9M$37.1M
Interest income (expense), net$2.9M-$1.0M-$6.5M
Other expense, net-$558.0K-$565.0K-$26.0K
Income from continuing operations before income tax$66.3M$57.3M$30.6M
Income tax provision (expense) benefit from continuing operations-$17.7M-$15.3M$36.8M
Net income from continuing operations$48.6M$42.0M$67.4M
Income (loss) from discontinued operations, net of tax$0$421.0K-$9.2M
Net income$48.6M$42.4M$58.2M
Net income available to common stockholders from continuing operations$48.6M$42.0M$55.8M
Continuing operations - basic (in dollars per share)$0$0$0
Discontinued operations - basic (in dollars per share)$0$0-$0
Basic net income per common share (in dollars per share)$0.33$0.29$0.40
Continuing operations (in dollars per share)$0$0$0
Discontinued operations (in dollars per share)$0$0-$0
Diluted net income (loss) per common share (in dollars per share)$0.32$0.28$0.37
Weighted average shares outstanding - basic (in shares)147.8M shares147.0M shares116.5M shares
Weighted average shares outstanding - diluted (in shares)149.7M shares149.0M shares146.0M shares

Compare MIMEDX GROUP, INC. with another company

Leadership

Who has led MIMEDX GROUP, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Parker H. Petit2009–2018
  2. Todd Newton2022
  3. Joseph H. Capper2023–now

Chair

  1. Steve Gorlin2008
  2. Parker H. Petit2014–2018

President

  1. Ken Cleon Edwards2007–2008
  2. Rufus Lewis Bennett Sr.2008
  3. Brian J. Splan2008
  4. Parker H. Petit2009
  5. Rohit Kashyap2022

Chief financial officer

  1. John C. Thomas2008
  2. Michael J. Culumber2009
  3. Michael J. Senken2010–2018
  4. Edward Borkowski2018–2019
  5. Peter M. Carlson2020–2023
  6. Rice Doug2023–now

Chief operating officer

  1. Rebeccah Covert Brown2008–2009
  2. Ricci S. Whitlow2023–now
2010201520202025
Board members and other officers (38)

Former names

  • Alynx, Co.Mar 6, 2007 to Apr 2, 20082

Timeline

  1. Jan 31, 2023New chief executive Joseph H. Capper becomes CEO11
  2. Sep 19, 2022New chief executive Todd Newton becomes CEO12
  3. Feb 26, 2009New chief executive Parker H. Petit becomes CEO13

Filings

310 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 64 major events, 145 insider forms, 16 large holders, 64 other. The latest 20:

  1. Sep 4, 2026EFFECT EDGAR
  2. Sep 4, 2026424B3 PROSPECTUS EDGAR
  3. Aug 25, 2026S-4 REGISTRATION STATEMENT EDGAR
  4. Aug 11, 2026425 EDGAR
  5. Aug 11, 20268-K/A EDGAR
  6. Jul 30, 2026425 EDGAR
  7. Jul 30, 2026425 EDGAR
  8. Jul 29, 2026425 EDGAR
  9. Jul 29, 20268-K EDGAR
  10. Jul 29, 2026425 EDGAR
  11. Jul 29, 202610-Q EDGAR
  12. Jul 29, 20268-K EDGAR
  13. Jul 29, 2026425 EDGAR
  14. Jul 29, 2026425 EDGAR
  15. Jul 7, 20264 EDGAR
  16. Jun 25, 20264 EDGAR
  17. Jun 16, 20268-K EDGAR
  18. Jun 12, 20264 EDGAR
  19. Jun 12, 20264 EDGAR
  20. Jun 12, 20264 EDGAR

The 310 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 16 such filings since October 2021, the latest 10:

  1. Feb 13, 2026SCHEDULE 13G/A
  2. Nov 12, 2024SC 13G/A
  3. Nov 8, 2024SC 13G/A
  4. Nov 7, 2024SC 13G
  5. Nov 4, 2024SC 13G/A
  6. Oct 22, 2024SC 13G/A
  7. Feb 13, 2024SC 13G/A
  8. Jan 25, 2024SC 13G/A
  9. Dec 27, 2023SC 13D/A
  10. Feb 9, 2023SC 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Essex Woodlands Management, Inc.28,195,249$108.6M42.7%No change
BlackRock, Inc.12,154,466$46.8M0.0%+243,166
Nantahala Capital Management, LLC9,535,104$36.7M1.1%+6,137,805
Trigran Investments, Inc.7,173,770$27.6M5.1%−1,339
State Street Corp5,578,920$21.5M0.0%+522,119
Vanguard Capital Management LLC5,187,053$20.0M0.0%+21,047
Paradigm Capital Management Inc/ny4,073,100$15.7M0.4%+662,800
Geode Capital Management, LLC3,143,488$12.1M0.0%+262,329
Goldman Sachs Group Inc2,665,562$10.3M0.0%+1,480,001
Aqr Capital Management LLC2,467,005$9.5M0.0%+1,554,277
Renaissance Technologies LLC2,444,230$9.4M0.0%−575,641
Punch & Associates Investment Management, Inc.2,058,089$7.9M0.4%+38,371
Dimensional Fund Advisors LP1,944,852$7.5M0.0%−749,150
Cannell Capital LLC1,870,436$7.2M5.0%+373,250
Northern Trust Corp1,317,575$5.1M0.0%+294,469
Vanguard Portfolio Management LLC1,290,476$5.0M0.0%+184,758
Arrowstreet Capital, Limited Partnership1,266,571$4.9M0.0%+490,730
Charles Schwab Investment Management Inc1,241,916$4.8M0.0%−137,249
Meros Investment Management, LP1,121,929$4.3M1.4%+28,901
Morgan Stanley1,043,286$4.0M0.0%+230,544
Qube Research & Technologies Ltd990,228$3.8M0.0%−661,291
Citadel Advisors LLC825,838$3.2M0.0%+49,397
Jane Street Group, LLC792,311$3.1M0.0%+266,839
Vanguard Fiduciary Trust Co775,085$3.0M0.0%−47,884
Kennedy Capital Management LLC770,075$3.0M0.1%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63